metadata:
  name: test
  currency: GBP
  effective_date: '2025-01-01'
  version: '1.0'
  source: protocols/cost_configs/aflibercept_2mg_nhs_2025.yaml
  created: '2025-06-23T23:15:57.307784'
  based_on: 'Cost Config: aflibercept_2mg_nhs_2025'
drug_costs:
  aflibercept_2mg:
    unit_cost: 457.0
    list_price: 816
    procurement_discount: 0.44
    note: Based on current market pricing
  aflibercept_2mg_biosimilar:
    unit_cost: 228.0
    list_price: 400
    procurement_discount: 0.43
    note: Projected pricing - ~50% of originator net price
visit_components:
  injection: 151.0
  oct_scan: 76.0
  visual_acuity_test: 26.0
  pressure_check: 11.0
  virtual_review: 51.0
  face_to_face_review: 121.0
  nurse_review: 40.0
  clinical_exam: 30.0
  fluorescein_angiography: 150.0
  adverse_event_assessment: 201.0
  brief_check: 15.0
  consultation: 61.0
visit_types:
  injection_loading:
    components:
    - injection
    - visual_acuity_test
    - brief_check
    total_override: null
    note: Streamlined loading phase visit
    total_cost: 190.0
    decision_maker: false
  injection_virtual:
    components:
    - injection
    - oct_scan
    - pressure_check
    - virtual_review
    total_override: null
    note: Standard maintenance injection with virtual review
    total_cost: 285.0
    decision_maker: false
  injection_face_to_face:
    components:
    - injection
    - oct_scan
    - visual_acuity_test
    - pressure_check
    - face_to_face_review
    total_override: null
    note: Full assessment with injection
    total_cost: 380.0
    decision_maker: false
  monitoring_virtual:
    components:
    - oct_scan
    - visual_acuity_test
    - virtual_review
    total_override: null
    note: Assess and extend visit without injection
    total_cost: 150.0
    decision_maker: false
  monitoring_face_to_face:
    components:
    - oct_scan
    - visual_acuity_test
    - pressure_check
    - face_to_face_review
    total_override: null
    note: Full monitoring without injection
    total_cost: 230.0
    decision_maker: false
  initial_assessment:
    components:
    - oct_scan
    - visual_acuity_test
    - fluorescein_angiography
    - face_to_face_review
    - consultation
    total_override: 380
    note: Comprehensive initial assessment
    total_cost: 380.0
    decision_maker: false
  annual_review:
    components:
    - oct_scan
    - visual_acuity_test
    - clinical_exam
    - face_to_face_review
    - consultation
    total_override: null
    note: Annual treatment review
    total_cost: 310.0
    decision_maker: false
special_events:
  initial_assessment: 380.0
  discontinuation_admin: 50.0
  retreatment_assessment: 200.0
  adverse_event_mild: 500.0
  adverse_event_severe: 2000.0
  treatment_switch_assessment: 150.0
  treatment_switch_reload: 100.0
visit_costs:
  injection_visit_standard:
    drug_cost: 457
    procedure_cost: 285
    total_cost: 742
  injection_visit_loading:
    drug_cost: 457
    procedure_cost: 190
    total_cost: 647
  monitoring_visit_standard:
    drug_cost: 0
    procedure_cost: 150
    total_cost: 150
annual_costs:
  aflibercept_2mg_typical:
    year_1:
      loading_injections: 3
      maintenance_injections: 3.9
      total_injections: 6.9
      drug_cost: 3153
      procedure_costs: 1970
      annual_total: 5123
    year_2_plus:
      injections: 5.2
      drug_cost: 2376
      procedure_costs: 1480
      annual_total: 3856
  aflibercept_2mg_fixed_q8:
    injections_per_year: 6.5
    drug_cost: 2971
    procedure_costs: 1850
    annual_total: 4821
cost_effectiveness:
  nice_threshold_per_qaly: 30000
  typical_utility_gain: 0.1
  implied_max_annual_cost: 3000
cost_notes:
  major_cost_driver: Drug cost represents ~60-65% of total
  biosimilar_impact: Could reduce total costs by 30-35%
  interval_extension: "Each 2-week extension saves ~\xA395 per patient"
  virtual_clinics: "Save \xA370 per visit vs face-to-face"
